<bill session="117" type="s" number="1548" updated="2023-03-08T20:12:26Z">
  <state datetime="2021-05-11">REFERRED</state>
  <status>
    <introduced datetime="2021-05-11"/>
  </status>
  <introduced datetime="2021-05-11"/>
  <titles>
    <title type="display">ENACT Act of 2021</title>
    <title type="official" as="introduced">A bill to amend the Public Health Service Act to improve the diversity of participants in research on Alzheimer's disease, and for other purposes.</title>
    <title type="short" as="introduced">ENACT Act of 2021</title>
    <title type="short" as="introduced">Equity in Neuroscience and Alzheimer&#226;&#8364;&#8482;s Clinical Trials Act of 2021</title>
  </titles>
  <sponsor bioguide_id="L000570"/>
  <cosponsors>
    <cosponsor bioguide_id="B001267" joined="2021-05-27"/>
    <cosponsor bioguide_id="B001288" joined="2022-06-07"/>
    <cosponsor bioguide_id="B001236" joined="2021-12-07"/>
    <cosponsor bioguide_id="C001047" joined="2022-05-17"/>
    <cosponsor bioguide_id="C001070" joined="2021-06-17"/>
    <cosponsor bioguide_id="C001075" joined="2021-12-07"/>
    <cosponsor bioguide_id="C001035" joined="2021-05-11"/>
    <cosponsor bioguide_id="H000273" joined="2022-08-01"/>
    <cosponsor bioguide_id="I000024" joined="2022-05-19"/>
    <cosponsor bioguide_id="K000377" joined="2022-09-12"/>
    <cosponsor bioguide_id="M000133" joined="2022-05-04"/>
    <cosponsor bioguide_id="M000934" joined="2021-10-26"/>
    <cosponsor bioguide_id="M001153" joined="2022-05-19"/>
    <cosponsor bioguide_id="P000595" joined="2022-05-04"/>
    <cosponsor bioguide_id="S001191" joined="2021-10-07"/>
    <cosponsor bioguide_id="S001203" joined="2021-11-16"/>
    <cosponsor bioguide_id="S000770" joined="2021-11-16"/>
    <cosponsor bioguide_id="W000437" joined="2022-05-10"/>
  </cosponsors>
  <actions>
    <action datetime="2021-05-11">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2021-05-11" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="h" number="3085" relation="identical"/>
    <bill session="117" type="s" number="4486" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Congressional oversight"/>
    <term name="Health facilities and institutions"/>
    <term name="Health programs administration and funding"/>
    <term name="Health promotion and preventive care"/>
    <term name="Higher education"/>
    <term name="Medical research"/>
    <term name="Minority education"/>
    <term name="Minority employment"/>
    <term name="Minority health"/>
    <term name="Neurological disorders"/>
    <term name="Research administration and funding"/>
  </subjects>
  <amendments/>
  <summary date="2021-11-10T19:18:50Z" status="Introduced in Senate">Equity in Neuroscience and Alzheimer's Clinical Trials Act of 2021 or the ENACT Act of 2021

This bill sets out activities and requirements to increase the participation of underrepresented populations in research and clinical trials for Alzheimer's disease and related dementias.

Specifically, the National Institute on Aging (NIA) must establish and provide technical assistance to Alzheimer's research centers located in areas with higher concentrations of minority groups. These centers must

 establish diagnostic and treatment clinics designed to serve minority, rural, and other underserved populations; operate clinical trials; and carry out public outreach to encourage members of minority populations to participate in clinical trials and research. Additionally, the NIA must disseminate information to members of minority populations about participating in clinical trials and take other actions to enhance diversity with respect to the Alzheimer's research that it conducts or supports.

The bill also directs the NIA to increase diversity among Alzheimer's researchers by encouraging the participation of individuals who are from groups that are underrepresented in clinical, behavioral, and social sciences.</summary>
</bill>
